Latest Insider Transactions at Catalent, Inc. (CTLT)
This section provides a real-time view of insider transactions for Catalent, Inc. (CTLT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Catalent, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Catalent, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 01
2021
|
Ricardo Pravda Chief Transformation Officer |
SELL
Open market or private sale
|
Direct |
4,906
-29.46%
|
$647,592
$132.68 P/Share
|
|
Oct 01
2021
|
Ricardo Pravda Chief Transformation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,818
+10.43%
|
$271,078
$71.52 P/Share
|
|
Sep 01
2021
|
John R Chiminski Executive Chair |
SELL
Bona fide gift
|
Direct |
11,000
-4.79%
|
-
|
|
Aug 27
2021
|
Christa Kreuzburg Director |
SELL
Payment of exercise price or tax liability
|
Direct |
199
-2.27%
|
$25,671
$129.85 P/Share
|
|
Aug 27
2021
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Open market or private sale
|
Direct |
452
-0.48%
|
$58,760
$130.74 P/Share
|
|
Aug 27
2021
|
John R Chiminski Executive Chair |
SELL
Open market or private sale
|
Direct |
44,488
-8.21%
|
$5,783,440
$130.76 P/Share
|
|
Aug 27
2021
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
6,111
-3.81%
|
$794,430
$130.74 P/Share
|
|
Aug 27
2021
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
2,262
-1.9%
|
$294,060
$130.74 P/Share
|
|
Aug 27
2021
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
1,698
-5.26%
|
$220,740
$130.74 P/Share
|
|
Aug 27
2021
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
4,173
-6.6%
|
$542,490
$130.61 P/Share
|
|
Aug 27
2021
|
Alessandro Maselli President & CEO |
SELL
Open market or private sale
|
Direct |
3,743
-6.37%
|
$486,590
$130.74 P/Share
|
|
Aug 27
2021
|
Ricardo Pravda Chief Transformation Officer |
SELL
Open market or private sale
|
Direct |
692
-2.57%
|
$89,960
$130.74 P/Share
|
|
Aug 27
2021
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
1,471
-3.54%
|
$191,230
$130.74 P/Share
|
|
Aug 27
2021
|
Kay A Schmidt SVP, Enterprise Functions |
SELL
Open market or private sale
|
Direct |
825
-2.46%
|
$107,250
$130.74 P/Share
|
|
Aug 27
2021
|
Thomas P Castellano SVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,093
-5.33%
|
$272,090
$130.74 P/Share
|
|
Aug 26
2021
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
BUY
Grant, award, or other acquisition
|
Direct |
7,830
+14.23%
|
-
|
|
Aug 26
2021
|
John R Chiminski Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
105,418
+27.76%
|
-
|
|
Aug 26
2021
|
Steven L Fasman EVP & Chief Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,566
+12.54%
|
-
|
|
Aug 26
2021
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Grant, award, or other acquisition
|
Direct |
8,008
+11.82%
|
-
|
|
Aug 26
2021
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
4,984
+23.47%
|
-
|
|
Aug 26
2021
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
6,052
+21.4%
|
-
|
|
Aug 26
2021
|
Alessandro Maselli President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,008
+21.27%
|
-
|
|
Aug 26
2021
|
Ricardo Pravda Chief Transformation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,030
+13.05%
|
-
|
|
Aug 26
2021
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
BUY
Grant, award, or other acquisition
|
Direct |
4,317
+17.14%
|
-
|
|
Aug 26
2021
|
Kay A Schmidt SVP, Enterprise Functions |
BUY
Grant, award, or other acquisition
|
Direct |
2,590
+13.36%
|
-
|
|
Aug 26
2021
|
Thomas P Castellano SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,273
+17.75%
|
-
|
|
Jul 26
2021
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
BUY
Grant, award, or other acquisition
|
Direct |
885
+2.2%
|
-
|
|
Jul 26
2021
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Open market or private sale
|
Direct |
120
-0.31%
|
$13,560
$113.05 P/Share
|
|
Jul 26
2021
|
John R Chiminski Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
16,461
+8.88%
|
-
|
|
Jul 26
2021
|
John R Chiminski Executive Chair |
SELL
Open market or private sale
|
Direct |
11,137
-6.81%
|
$1,258,481
$113.05 P/Share
|
|
Jul 26
2021
|
Steven L Fasman EVP & Chief Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,770
+2.5%
|
-
|
|
Jul 26
2021
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
1,549
-2.25%
|
$175,037
$113.05 P/Share
|
|
Jul 26
2021
|
Karen Flynn Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,151
+3.12%
|
-
|
|
Jul 26
2021
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Grant, award, or other acquisition
|
Direct |
885
+1.68%
|
-
|
|
Jul 26
2021
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
465
-0.91%
|
$52,545
$113.05 P/Share
|
|
Jul 26
2021
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
974
+5.25%
|
-
|
|
Jul 26
2021
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
451
-2.64%
|
$50,963
$113.05 P/Share
|
|
Jul 26
2021
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
753
+4.45%
|
-
|
|
Jul 26
2021
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
1,079
-3.32%
|
$121,927
$113.04 P/Share
|
|
Jul 26
2021
|
Alessandro Maselli President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,009
+12.21%
|
-
|
|
Jul 26
2021
|
Alessandro Maselli President & CEO |
SELL
Open market or private sale
|
Direct |
993
-5.06%
|
$112,209
$113.05 P/Share
|
|
Jul 26
2021
|
Ricardo Pravda Chief Transformation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
885
+7.15%
|
-
|
|
Jul 26
2021
|
Ricardo Pravda Chief Transformation Officer |
SELL
Open market or private sale
|
Direct |
458
-4.14%
|
$51,754
$113.05 P/Share
|
|
Jul 26
2021
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
BUY
Grant, award, or other acquisition
|
Direct |
496
+2.91%
|
-
|
|
Jul 26
2021
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
360
-2.19%
|
$40,680
$113.05 P/Share
|
|
Jul 26
2021
|
Kay A Schmidt SVP, Enterprise Functions |
BUY
Grant, award, or other acquisition
|
Direct |
885
+5.87%
|
-
|
|
Jul 26
2021
|
Kay A Schmidt SVP, Enterprise Functions |
SELL
Open market or private sale
|
Direct |
547
-3.94%
|
$61,811
$113.05 P/Share
|
|
Jul 26
2021
|
Thomas P Castellano SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,062
+6.4%
|
-
|
|
Jul 26
2021
|
Thomas P Castellano SVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
555
-3.7%
|
$62,715
$113.05 P/Share
|
|
Jul 26
2021
|
Ricci S Whitlow President, CSS |
BUY
Grant, award, or other acquisition
|
Direct |
531
+14.6%
|
-
|